Similarly, our study demonstrated that decreased DDX11 expression in RCC increases the sensitivity to PARP inhibitors, indicating that DDX11-deficient RCCs share some features with BRCAness tumors. This evidence concerns the gene DDX11 and renal cell carcinoma.